consolidation chemotherapy

Phase 3Small molecule

SShenzhen People's Hospital

consolidation chemotherapy is one of 58 small molecule programs targeting Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerNot yet recruiting

Total Neoadjuvant TherapyUnknown status

Rectal NeoplasmsRecruiting

Lung CancerPhase 2

Not yet recruiting

Total Neoadjuvant TherapyPhase 3

Unknown status

Rectal NeoplasmsPreclinical

Recruiting

Competition

Competitive Landscape

199 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

25 2

Beyfortus

BeiGene

Phase 3

10 3

Abraxane

Bristol-Myers Squibb

Phase 3

7 4

Zepzelca

Jazz Pharmaceuticals

Phase 3

3 5

Alecensa

Roche

Phase 3

3 6

Tarlatamab-Dznl

Amgen

Phase 3

2 7

DATROWAY

Daiichi Sankyo

Phase 3

2 8

Ilaris

Novartis

Phase 3

2 9

Hycamtin

MMeitheal

Phase 3

6 10

Alimta

EEagle Pharmaceuticals, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Rectal Neoplasms

NCT05496491

Q4 2029

Phase 2/3Recruiting

Total Neoadjuvant Therapy

NCT06758830

Q4 2030

Phase 2Not yet recruiting

Lung Cancer

NCT07858253

Phase 3Active, not recruiting

Rectal Cancer

NCT06246344

Clinical

Trials by Indication[1]

Locally-advanced Rectal Cancer2 trials

Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer

Completed·SShenzhen People's Hospital·Phase 2·NCT05792735·27 enrolled

Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer

Completed·—·Phase 2·NCT05274945·58 enrolled

Total Neoadjuvant Therapy2 trials

Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.

Recruiting·—·Phase 2/3·NCT06758830·400 enrolled

Total Neoadjuvant Therapy in Rectal Cancer Treatment

Unknown status·SState Scientific Centre of Coloproctology, Russian Federation·Phase 4·NCT04747951·280 enrolled

Chemoradiotherapy1 trial

A Prospective Phase II Study of Individualized Neoadjuvant Chemoradiotherapy for Rectal Cancer Based on Recurrence Risk

Unknown status·—·Phase 2·NCT04664504·150 enrolled

Myeloid Neoplasm1 trial

Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

Completed·HHospital Israelita Albert Einstein·Phase 2·NCT02084563·455 enrolled

Acute Myeloid Leukemia1 trial

Leukemia Stem Cell Detection in Acute Myeloid Leukemia

Terminated·WWake Forest University Health Sciences·Phase 3·NCT02927938·18 enrolled

3 more indications

Lung Cancer1 trial

CLEAR-Lung III: Circulating Tumor DNA-Guided Consolidation Chemotherapy and Immunotherapy After Chemoradiation in Unresectable Stage III NSCLC

Not yet recruiting·AAnusha Chidharla, MD·Phase 2·NCT07858253·43 enrolled

Rectal Cancer1 trial

Online Adaptive Radiotherapy With a Boost to the Primary Tumor and Clinically Involved Lymph Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer: A Prospective, Randomized Controlled Trial

Active, not recruiting·SShandong Cancer Hospital and Institute·Phase 3·NCT06246344·128 enrolled

Rectal Neoplasms1 trial

Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial

Recruiting·LLarissa University Hospital·Preclinical·NCT05496491·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for consolidation chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — consolidation chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for consolidation chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShenzhen People's Hospital

consolidation chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Q4 2029

Q4 2030

Trials by Indication[1]

Locally-advanced Rectal Cancer2 trials

Total Neoadjuvant Therapy2 trials

Chemoradiotherapy1 trial

Myeloid Neoplasm1 trial

Acute Myeloid Leukemia1 trial

Lung Cancer1 trial

Rectal Cancer1 trial

Rectal Neoplasms1 trial

References

Drug Info

Quick Facts

Related News